

REMARKS

Amendments

The Claims are amended as herein described solely to expedite prosecution. The Claims as herein amended do not add new matter and are supported by the application as originally filed, for example, by the Claims as originally filed. Applicants respectfully request entry of the amended Claims. All amendments and cancellations are made without prejudice. Applicants reserve the right to pursue cancelled or amended subject matter in one or more timely filed continuation, continuation-in-part, or divisional applications.

Restriction Requirement

Restriction to one of the following inventions was required by the Office under 35 USC § 121 and 372:

- I. Claims 1-19 and 44-47, drawn to anti-IL-4R antibodies and compositions thereof.
- II. Claims 20-26, drawn to isolated nucleic acids encoding Vh or Vl domains of anti-IL-4R antibodies, vectors and host cells thereof.
- III. Claims 27-29, drawn to methods of making the antibody of claim 1.
- IV. Claims 30-43 drawn to methods of treatment comprising administering the antibody of claim 1.

Applicants elect, with traverse, the claims of **Group I** for examination.

Species Selection

Selection of an antibody species was required under 35 U.S.C. § 121.

Applicants select, with traverse, the antibody species designated L2H14.

- Vh = H14 = SEQ ID NO:42
- Vl = L2 = SEQ ID NO:6

The CDR and FR regions of these sequences are as illustrated in Figure 3:

- L2 (SEQ ID NO:6)
FR1 = residues 1-23, CDR1 = residues 24-35, FR2 = residues 36-50, CDR2 = residues 51-57, FR3 = residues 58-89, CDR3 = 90-99, and FR4 = residues 100-109
- H14 (SEQ ID NO:42)

FR1 = residues 1-30, CDR1 = residues 31-35, FR2 = residues 36-49, CDR2 = residues 50-65, FR3 = residues 66-97, CDR3 = residues 98-104, and FR4 = residues 105-115

As Applicants have restricted, with traverse, to the invention of Group I, it is not believed that a further election to a particular disease state is required. Solely in the interest of expediting prosecution, however, should such an election be deemed necessary, Applicants elect the disease of asthma.

Each of the pending, non-withdrawn claims reads on the elected antibody species.

CONCLUSION

A favorable action is respectfully requested. Should the Examiner believe that any issues could be resolved by way of a teleconference, the Examiner is invited to telephone the undersigned representative of the Applicants, to discuss resolution thereof.

Respectfully submitted,

/Nathan A. Machin/

Nathan A. Machin
Attorney/Agent for Applicant(s)
Registration No.: 47,763
Phone: (206) 265-8779
Date: December 9, 2008

Please send all future correspondence to:

22932
Immunex Corporation
Law Department
1201 Amgen Court West
Seattle, Washington 98119-3105
(206) 265-7000